Gelomics Expands Global Presence with New Distribution Partner, Voden Medical In Italy

Gelomics is pleased to announce a strategic partnership with Voden Medical, a renowned provider of advanced diagnostic and life science solutions in Italy. Under this agreement, Voden Medical will serve as Gelomics’ exclusive distributor in the Italian market. This partnership, effective January 2025, marks a significant step forward in Gelomics’ mission to bring our innovative […]

Gelomics partners with Bucher Biotec AG for Product Distribution in Switzerland

Gelomics is pleased to announce a new strategic partnership with Bucher Biotec AG, a leading provider of advanced life science solutions in Switzerland & Lichtenstein. Under this agreement, Bucher Biotec will serve as Gelomics’ exclusive distributor across the Swiss market. This partnership marks an important milestone for Gelomics as we expand our presence in Europe. […]

Gelomics announces appointment of Distinguished Professor Dietmar W. Hutmacher, PhD, MBA and Professor Travis J. Klein, PhD to its Scientific Advisory Board

Gelomics, a leading Australian biotech firm at the forefront of drug development innovation, is delighted to further strengthen its Scientific Advisory Board with the addition of Distinguished Professor Dietmar W. Hutmacher, PhD, MBA, and Professor Travis J. Klein, PhD. Following the recent appointment of Professor Dame Molly Stevens, FREng FRS, these new appointments reinforce our […]

LunaGel™ Ultrapure GelMA ECM Is Now Available

We’re thrilled to unveil our latest innovation: LunaGel™ Ultrapure GelMA Photocrosslinkable Extracellular Matrix (ECM), now available in both High Stiffness and Low Stiffness options. Developed in collaboration with Rousselot Biomedical, this breakthrough leverages the advanced X-Pure® GelMA technology, setting a new standard for 3D cell culture by offering unparalleled control over matrix porosity and stiffness. […]

Subscribe Now!